By Leroy Leo and Patrick Wingrove
(Reuters) – Moderna Inc on Thursday raised its annual forecast for COVID-19 vaccine gross sales to as much as $8 billion on hopes of a lift within the fall season as gross sales transfer to a personal market in the USA from authorities contracts, sending its shares up 6% in premarket buying and selling.
COVID vaccine makers Moderna and Pfizer are pinning their hopes on personal markets gross sales and robust demand for his or her new up to date pictures focusing on XBB.1.5 variant to show round a droop in gross sales of the merchandise that had bumper development throughout the peak of the pandemic.
Moderna expects $6 billion to $8 billion in gross sales from its COVID pictures this yr, up from its earlier forecast of $5 billion, pushed by potential U.S. demand for 50 to 100 million doses within the fall season.
The corporate sees between $2 billion and $4 billion within the vaccine gross sales from business contracts in the USA and different locations. Nevertheless, it mentioned $1 billion of a complete $5 billion in gross sales from signed authorities contracts can be deferred to subsequent yr.
Pfizer on Tuesday warned that gross sales of COVID vaccines have been unsure, including that the COVID vaccination charges this fall must be a great predictor for annual charges. Gross sales of Pfizer’s COVID-19 vaccine fell 83% within the second quarter.
For Moderna, second-quarter COVID vaccine gross sales slumped 94% to $293 million, which was nonetheless larger than analysts’ common estimate of $233.6 million, based on Refinitiv information.
It reported a internet lack of $3.62 per share, narrower than analysts’ common estimate of a $4.04 loss.
Moderna’s quarterly financials have been harm by stock writedowns and different expenses price $674 million, pushed by a shift in product demand to the up to date COVID shot in addition to a decline in buyer demand.
(Reporting by Leroy Leo in Bengaluru and Patrick Wingrove in New York; Modifying by Shinjini Ganguli)